Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010610:Pharyngeal Neoplasms / Q000188:drug therapy; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy*; D013584:Sarcoma, Synovial / Q000188:drug therapy; D014750:Vincristine / Q000008:administration & dosage*
D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate